Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03281538 · ClinicalTrials.gov registry record · Phase 3
Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
A Phase 3 study of Uremic Pruritus, sponsored by Cara Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 288
- Enrollment target
- 20
- Study locations
NCT03281538: Completed Phase 3 study of Uremic Pruritus, sponsored by Cara Therapeutics.
NCT03281538 is a Phase 3 study of Uremic Pruritus that has completed, run by Cara Therapeutics. The registered enrollment target is 288 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03281538, a Phase 3 study of Uremic Pruritus, has completed, sponsored by Cara Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 288 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label multicenter, long-term extension safety study to evaluate the safety of IV CR845 administered after each dialysis session over a Treatment Period of up to 52 weeks.
Primary Outcome
Assessed by physical examination, monitoring of adverse events, vital signs and laboratory assessments
Conditions Studied
Interventions
- DRUG CR845
Study Locations (20)
California
- Cara Therapeutics Study Site - Chula Vista
- Cara Therapeutics Study Site - El Centro
- Cara Therapeutics Study Site - Long Beach
- Cara Therapeutics Study Site - Northridge
Florida
- Cara Therapeutics Study Site - Hollywood
- Cara Therapeutics Study Site - Tampa
- Cara Therapeutics Study Site - Winter Park
Georgia
- Cara Therapeutics Study Site - Albany
- Cara Therapeutics Study Site - Augusta
New Mexico
- Cara Therapeutics Study Site - Albuquerque
- Cara Therapeutics Study Site - Gallup
New York
- Cara Therapeutics Study Site - Mineola
- Cara Therapeutics Study Site - Ridgewood
Colorado
- Cara Therapeutics Study Site - Denver
Idaho
- Cara Therapeutics Study Site - Meridian
Massachusetts
- Cara Therapeutics Study Site - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 288 participants |
| Start Date | 2017-08-14 |
| Est. Completion | 2020-02-11 |
| Phase | Phase 3 |
What the finished NCT03281538 record still lists
NCT03281538 is an interventional study that assigns participants to a tested intervention. The registered 288 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Uremic Pruritus appearing as the primary indexed condition, and to 1 intervention - of which CR845 is the first listed.
NCT03281538 names 20 study sites across 12 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT03281538 about?
NCT03281538 is a clinical study titled "Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus". This is an open-label multicenter, long-term extension safety study to evaluate the safety of IV CR845 administered after each dialysis session over a Treatment Period of up to 52 weeks.
What is the current status of trial NCT03281538?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 288 participants. The study started on 2017-08-14. Estimated completion is 2020-02-11.
What conditions does trial NCT03281538 study?
This clinical trial studies the following conditions: Uremic Pruritus.
What interventions are being tested in trial NCT03281538?
The interventions under investigation include: CR845 (DRUG).
Who is sponsoring clinical trial NCT03281538?
This trial is sponsored by Cara Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03281538 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uremic Pruritus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03281538's enrollment target sits among peer trials
288 1174th of 2000 higher than 819 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02098265 · 288 participants · NA
A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device
- NCT03741777 · 288 participants · NA
Comparison of Residual Gastric Volume Between Children Who Drink Different Clear Oral Fluid Volume
- NCT03937635 · 288 participants · Phase 3
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
- NCT04621877 · 288 participants · NA
Lay-Delivered Behavioral Activation in Senior Centers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI